Navigation Links
HUYA BIOSCIENCE INTERNATIONAL ENGAGES IN PARTNERSHIP WITH LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE
Date:7/8/2011

SAN DIEGO, July 8, 2011 /PRNewswire/ -- HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Liaoning (Benxi) Bio-pharmaceutical Industry Base. The collaboration agreement will combine both parties' strength in aiding the advancement of China's drug innovation platform.

HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing clinical stage compounds from the country, utilizing its expertise to advance these compounds for global markets.

Liaoning (Benxi) Bio-pharmaceutical Industry Base is the third national biomedical industry base approved by the National Ministry of Science and Technology. Located between Benxi and Shenyang, Liaoning (Benxi) Bio-pharmaceutical Industry Base is now the northeast pharmaceutical center and has attracted both domestic and foreign pharmaceutical companies and research institutions to assemble at this base, including Shenyang Pharmaceutical University, Liaoning Analytical Science Research Institute, and Liaoning TCM Research Institute.

Under the agreement, Liaoning (Benxi) Bio-pharmaceutical Industry Base and HUYA will collaborate to promote new drug development. HUYA will have the first opportunity to provide assistance in evaluating research and development projects conducted by pharmaceutical enterprises residing in Liaoning (Benxi) Bio-pharmaceutical Industry Base. HUYA will also be able to globalize select programs from Liaoning (Benxi) Bio-pharmaceutical Industry Base through HUYA's innovative co-development model and worldwide pharmaceutical partners.

"It's a great honor to form the partnership with Liaoning (Benxi) Bio-pharmaceutical Industry Base," said Clement Gingras, HUYA's CTO and COO, China. "Together, we will help promote the acceleration and development of China's emerging biopharmaceutical industry."

Xiaofan Zhang, Vice Director of Liaoning (Benxi) Bio-pharmaceutical Industry Base, commented, "Liaoning (Benxi) Bio-pharmaceutical Industry is committed to becoming the 'pharmaceutical valley' in northern China; with HUYA's knowledge and capacity in international drug development, Liaoning (Benxi) Bio-pharmaceutical Industry Base hopes to solidify its position as a leading medical and pharmaceutical base in China."

ABOUT HUYA BIOSCIENCE INTERNATIONAL

HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com.

ABOUT LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE

Liaoning (Benxi) Bio-pharmaceutical Industry Base is situated in between Benxi and the Liaoning provincial capital, Shenyang. It spans an area of 205 square km. Up to date, 264 enterprises have invested a total of 73.9 billion RMB ($11.4 billion) in the pharmaceutical base, with accumulated production capacity of 98 billion RMB ($15.1 billion). In 2010, with the approval from Ministry of Science and Technology, Liaoning (Benxi) Bio-pharmaceutical Industry Base formally became a national-level high-tech industry base.  For more information, please visit www.benxi.gov.cn  

CONTACT

USA:
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
+1.858.798.8800
ywang@huyabio.com

China:
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International
+86.21.51323312
vxia@huyabio.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Coronado Biosciences Closes $25.8M in Series C Financing
2. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
3. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
4. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
5. BIOSCIENCE EAST, the Life Sciences Industry Map, Highlighting Global Leaders in Healthcare Innovation, Kicks Off 5th Edition
6. Generex Announces Intention to Dividend a Portion of Anticipated Amarantus BioSciences Shares to Its Shareholders upon a Reverse Stock Split
7. Neurocrine Biosciences to Present at the Jefferies 2011 Global Healthcare Conference
8. Generex in Agreement to License RapidMist™ Technology for $10 Million to Amarantus BioSciences for Use With Its Proprietary MANF Proteins
9. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
10. Sangamo BioSciences and Collaborators Present Data Showcasing Broad Applications of ZFP Therapeutics®
11. BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):